AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo

Despite the initial response to the reversible, ATP-competitive quinazoline inhibitors that target ErbB-family, such a subset of cancer patients almost invariably develop resistance. Recent studies have provided compelling evidence that irreversible ErbB inhibitors have the potential to override thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Hua, Lin, Liping, Tong, Linjiang, Jiang, Yong, Zheng, Mingyue, Chen, Zhuo, Jiang, Xiaoyan, Zhang, Xiaowei, Ren, Xiaowei, Qu, Wenchao, Yang, Yang, Wan, Hua, Chen, Yi, Zuo, Jianping, Jiang, Hualiang, Geng, Meiyu, Ding, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138742/
https://www.ncbi.nlm.nih.gov/pubmed/21789172
http://dx.doi.org/10.1371/journal.pone.0021487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138742/
https://www.ncbi.nlm.nih.gov/pubmed/21789172
http://dx.doi.org/10.1371/journal.pone.0021487

Ejemplares similares